Regeneron's Phase 2 COURAGE trial reports the investigational drug trevogrumab may reduce muscle loss alongside semaglutide. Review the 52-week findings.
At the European Association for the Study of Diabetes annual meeting in late 2026, Regeneron presented Phase 2 COURAGE trial results detailing how the investigational drug trevogrumab affected muscle mass during semaglutide-associated weight loss. The company noted the 52-week findings are in press with The Lancet.
Previous medical understanding of weight-loss medications centered on total body mass reduction without pharmacological mechanisms to selectively protect muscle tissue. Clinicians treating obesity typically relied on lifestyle interventions to mitigate the lean mass decline that routinely accompanies significant weight reduction. Protocols advised progressive resistance training and structured protein intake to help maintain physical function during treatment. The absence of approved medications to specifically shield muscle left a noticeable gap in standard care.
As women progress through their late thirties, forties, and fifties, the natural decline of estrogen introduces significant metabolic adjustments. This hormonal transition often accelerates the loss of lean tissue, compounding the physical challenges of maintaining functional strength. When medical weight-loss treatments induce rapid caloric deficits, the body frequently catabolizes muscle alongside stored fat to meet its energy demands. Without targeted interventions, this biological mechanism can leave a patient with a lower scale weight but an unfavorably altered ratio of fat to muscle.
Historically, clinicians possessed limited tools to halt this specific metabolic trade-off. Medical guidance consistently prioritized behavioral strategies, encouraging patients to consume adequate dietary protein and engage in frequent weight-bearing exercise. While these lifestyle habits remain cornerstones of good health, they demand relentless consistency and often struggle to completely override the catabolic effects of powerful weight-loss medications. The medical field recognized that a purely behavioral approach left many patients vulnerable to unintentional physical deconditioning during their treatment journey.
This biological reality presents distinct challenges for individuals navigating simultaneous shifts in body composition and baseline physical strength. Losing substantial lean tissue alongside fat can leave patients physically weaker, complicating long-term health outcomes. Women entering midlife face natural body composition changes that make maintaining structural muscle increasingly demanding. Clinical guidance recognized this difficulty but could only offer behavioral strategies to manage the risks associated with modern medical weight loss.
The conversation around weight management historically prioritized scale reductions over the qualitative composition of the weight being lost. Providers lacked targeted therapies that could directly address the biological mechanisms behind tissue breakdown during caloric deficits. This persistent limitation forced patients and clinicians to balance the benefits of fat reduction against the known costs to skeletal muscle. The medical community required new research to determine if investigational therapies could actively protect functional tissue during active weight loss.
Regeneron reported results from the Phase 2 COURAGE trial to study body composition changes during medical weight management. The study tested whether trevogrumab could preserve lean mass and muscle during semaglutide-associated weight loss in people with obesity. Trevogrumab is an investigational antibody that blocks myostatin, a protein that naturally regulates muscle growth. These early findings provide a preliminary look at how combining medications might influence tissue preservation over a prolonged period.
In the lower-dose portion of the trial, participants received treatments for 52 weeks to measure long-term bodily responses. The study design administered semaglutide 2.4 mg alongside either placebo or varying doses of the investigational antibody. Specifically, participants received semaglutide combined with either 25 mg of trevogrumab or 75 mg of trevogrumab. The 52-week timeframe allowed researchers to track gradual shifts in both fat and lean mass during sustained weight loss.
Here are the specific discoveries regarding the trial structure and physical measurements:
Researchers utilized dual-energy X-ray absorptiometry, commonly known as a DXA scan, to measure overall lean mass changes. DXA scans assess broad tissue categories, providing a percentage-based evaluation of fat, bone, and lean mass across the entire body. The trial results demonstrated a clear decline in total lean mass among participants receiving only the standard weight-loss medication. The combination groups experienced a comparatively smaller reduction in lean tissue over the same one-year timeframe.
At 52 weeks, DXA-measured lean mass had declined by 7.3% in the semaglutide plus placebo group. Conversely, the decline measured 5.8% with 25 mg trevogrumab and 4.2% with 75 mg trevogrumab. Regeneron described the latter results as 20.5% and 42.5% relative preservation of lean mass, respectively, compared with semaglutide plus placebo. These figures represent the proportion of lean tissue saved relative to the typical loss observed with standard treatment.
Key discoveries related to DXA-measured lean mass include the following data points:
The trial also incorporated a predefined MRI analysis to measure fat-free thigh muscle volume among participants with evaluable scans. MRI provides a different metric than DXA, focusing on localized muscle volume rather than whole-body lean mass percentages. These two measurement techniques describe distinct biological realities and cannot be treated as interchangeable evaluations of overall muscle health. The localized MRI estimates offered a highly specific look at structural tissue retention in the lower body.
At 52 weeks, Regeneron reported that the 25 mg and 75 mg trevogrumab groups preserved 71.8% and 68.9%, respectively, of the thigh muscle volume that would otherwise have been lost with semaglutide plus placebo. Reuters also reported the MRI finding as more than 70% preservation with the 75 mg dose, based on a summary of the data. These figures are relative preservation estimates drawn from the localized scan analysis, not absolute additions to baseline muscle. The data indicates retention of existing tissue rather than active growth of new muscle mass.
Clinicians rely on DXA scans for a broad assessment of total physical composition, allowing them to track systemic changes over time. MRI provides a highly localized view that highlights structural density in specific movement-critical areas like the thighs. Both measurements provide valuable information about how a patient responds to intensive medical weight management. However, interpreting these distinct metrics accurately requires understanding that localized volume preservation does not automatically translate to whole-body strength improvements.
Specific MRI discoveries from the evaluable scans include the following insights:
Many individuals researching nutrition and weight management options often wonder if combination therapies accelerate total scale weight reduction. The COURAGE trial data indicated that combining the myostatin inhibitor with a GLP-1 medication changed the composition of the weight lost, but not the total amount. Regeneron said adding lower-dose trevogrumab did not meaningfully increase the weight loss achieved with semaglutide alone. The potential benefit centers entirely on tissue quality rather than enhanced scale results.
For women evaluating their own health metrics, this distinction highlights the importance of looking beyond total body weight. Improving body composition involves maintaining metabolically active tissue, even if the total numerical drop on the scale remains unchanged. The trial findings reinforce the clinical perspective that weight quality matters just as much as weight quantity. Retaining strength-supporting tissue presents a distinct medical goal separate from simple caloric reduction.
Here are the specific discoveries regarding weight-loss outcomes:
Introducing any new investigational compound requires careful documentation of patient tolerability and potential side effects. These Phase 2 findings offer an initial safety profile, but they do not confirm a definitive clinical advantage over existing protocols. The trial monitored participants continuously over the 52-week period to capture any adverse reactions to the medication combinations. Tolerability remains a critical factor for any therapy intended to support long-term metabolic health.
In the lower-dose portion, at least one adverse event was reported in 77% of participants receiving trevogrumab and 82% of those receiving placebo. Nausea, constipation, diarrhea, and vomiting were among the most common events documented during the study. Regeneron explicitly stated that trevogrumab’s safety and efficacy have not been evaluated by a regulatory authority. These findings serve as preliminary research data rather than evidence of an established, broadly accessible treatment.
Specific safety updates and regulatory context include the following points:
Analyzing preliminary medical research requires distinguishing between interesting structural observations and proven therapeutic benefits. The company release detailing the COURAGE trial does not provide full baseline characteristics, randomization details, or group sizes for the publicly available results. This limited transparency means independent readers cannot fully assess the statistical power or demographic spread of the study cohort. Early pharmaceutical announcements frequently highlight relative percentages that require careful contextual framing to avoid misinterpretation.
For example, the MRI results only apply to participants with evaluable scans, and the exact number of individuals included in that specific analysis remains unstated. Furthermore, the two tested trevogrumab doses produced closely grouped MRI estimates, failing to establish that one concentration clearly outperformed the other on that localized measure. The reported data also notes a subgroup with low lean mass showed numerically more preservation, but this phrasing falls short of confirming a statistically significant subgroup benefit. These nuances illustrate why Phase 2 clinical trials function as stepping stones for further research rather than immediate directives for patient care.
Specific discoveries regarding data limitations include:
The current trial data focuses on a broad demographic of individuals with obesity, rather than addressing menopause-specific hormonal changes. While protecting muscle is crucial for women navigating midlife, these specific results do not immediately alter established care guidelines. Regeneron’s planned next step is a Phase 2 study of trevogrumab with GLP-1 receptor agonist-based therapies in older adults with obesity and decreased muscle mass and/or strength. This upcoming research may provide more relevant context for aging populations managing complex body composition shifts.
Understanding the full midlife body composition framework reveals why unprotected muscle loss presents a serious clinical challenge. For readers researching perimenopause and menopause changes, the defensible takeaway remains firmly grounded in general physiological mechanics. The trial raises an important research question about preserving muscle during medication-associated weight loss, but it does not report functional outcomes like improved daily mobility. Until further trials establish concrete improvements in physical capability, standard nutritional and behavioral protocols remain necessary.
Updated research protocols and future directions include:
This early trial establishes a concrete research foundation for combining myostatin inhibitors with GLP-1 medications, prompting future clinical studies focused on actively protecting metabolic health and functional strength in aging populations.
Evaluating preliminary research on muscle preservation during medical weight loss requires looking past isolated trial statistics to understand your broader physical foundation. We address the confusion about which midlife changes are hormonal and which have multiple causes, translating credible evidence into clear adult guidance without wellness hype so you can protect your structural health.
Follow Refemina for research-led insights on menopause, strength, metabolism, nutrition, skin, intimacy and confidence through midlife. New articles turn complex topics into clear, useful context.
Keep learning about the changes that shape energy, strength, confidence and wellbeing through midlife.
Explore Resources